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..  I.  BACKGROUND 
A..  THE  NEED  FOR  ACITON 
THE JUSTIF1CA 'ITON  FOR THE INITIAL PROPOSAL 
L 
- -
In 1985, the Commission White Paper on completing the internal market stated: 
"D{fferences in  intellectual property  laws have a direct lUld negative  impact on 
intra""Community  trade  lUld  on  the  ability  ofenterprises. tq  treat  the  common 
-market as a single environment for their economic activities{  .  .] The picture has 
recently been further complicated by the need to adapt existing trademark systems 
to technological chlUlge in a number of  areas including{  .  .] biotechnology{..] The 
Commission accordingly intends to propose to  the  Council measures concerning 
-patent protection of biotechnological inventions ... ".(!)  ·  ·  ·  · 
As a  result of intensive scientific research an:d major discoveries over the past four 
. decades  in  molecular  biology,  biotechnology  has  emerged  as  one  of the  most 
promising and crucial technologies. Modem biotechnology constitutes a growing 
range  of techniques,  procedures  and  processes,  such  as  cell  fusion,  r-DNA 
technology,  biocatalysis,  that  can  be· substituted  for  and  complement  classical 
biotechnologies of selective breeding and  fermentation.  It is  science-based,  the 
scientific input being the most crucial element of the technology trajectory. The 
gap between developments in  basic science and their research· and development 
applications is small and diminishing. The impact of  the processes, techniques and 
hardware represented by  biotechnolo&ry  is felt across a number of sectors:  health 
care, agriculture, environmental protection, foodstuffs and industry. 
2.  Consequently,· when .publishing  its  initial  proposal  in  1988<
2
\  the  Commission 
noted:  "The primary purpose of the modern patent system is to  promote technical 
innovation  as  the  major  factor  of economic  growth  by  encouraging  inventive . 
activity through rewarding inventors for their creative efforts. The patent system. 
J. 
(I) 
(2). 
(3) 
_  thus  secures  costly  investment  in  research  and  development  and  industrial 
exploitation of research results.  Simultaneously, the patent system encourages an 
early and beneficial dissemination of knowledge ·in the field of activity involved. 
which,. without such protection, might be kept secret"(
3
).  .  . 
The  initial  proposal· highlighted a  number of specific  problems  regarding  the 
application  of  the  patent  system  . to  biotechnology.  These  concerned  the 
interpretation to  be given to  the conventional patent-law concepts to be. applied 
from now on to biological material that is self-reproducible or reproduCible within. 
a  biological  system.  In  other  words, ·how  should  animate  material  be  treated 
compared with inanimate. material? The questions raised concerned the definitions 
of the terms "subject-matter of the patent", "invention", "novelty", "adequacy of 
description", "scope of protection", etc.  ·  .  . 
Commission ·White  Paper  for  the  European  Coun9il  in  Milan  (28-29 June 1985) 
"Completing the internal  market", COM(85) 310 final of 14 June 1985; paragraph 145 
et seq. 
COM(88) 496 final- SYN 159, 17 October 1988; OJ No C 10, 13.1.1989, p.  3. 
Op  .. cit.,  paragraph  II, p.  6. 
l 
.. 
~'  ... .. 
.  .  ..  .  .  .  I  .  .  .  .  ,  .  .  .  ·.  . 
4.  The applicable p·atent law i~ based on the Convention on the unification of certain 
··  _points of substantive. law on patents for invention, concluded in Strasbourg at.trye 
·Council of Europe on 27 November 1963.  Arriong other things, the Convention 
defines  the  conditions  go·veming  patentability- and  determines  a  number  of 
. exceptions to· patentabilityc
4l.  The content of the Convention was incorporated into 
·5. 
6. 
-7. 
'8. 
(4) 
(5) 
.  (6) 
· -the  Convention  on:  the  grant . of European  p~tents,  concluded  in · Munich  on 
5 October 1973.  Seventeen  European  countries  are.  now  party  ··  to·  the 
Munich Convention (referred to below as the Eur9pean Patent Convention.·:- EPC), 
fourteen of which are Member Statesc5l.  .·  ·  .  ·  ·  ·  ·  _  _  ··  . 
The Member States' laws on patents for·invemion have gradually. been harmonized 
· in line with the .EPC,'i.e. they have .incorporated· the ·content of the Convention  . 
. This process is the result of  .a Declaration on the adjustment of  national patent law,. 
adopted by the governments of the Member. States when the Agreement r~lating 
to Community patents 'was. signedc
6l.  ·  ·  ·  · 
Thus. the  Member States'  laws  ~n patents  tor  invention  and  the  EPC  contain .. 
provisions  written ·over thirtY  yeats  ago~ at a  time  when the scope ·offered by . 
' biotechnology could not be imagined.. .  '  .  . '  . 
·In the. a,bsence of a clear response to the questions outlin~d above, uncertainty .wjlL 
. increase.  That  uncertainty·· will  hamper the  free  movemettt of biotechnological 
products and investment in  research  and  development for new ,biotechnological · 
products and  processes~. Ho:w  can  we  be certain that the Member States' patent 
offices will  all  react in the same· way when  confronted· with patent. applications 
relating to .the same biotechnological inventiol)? And how can we be sure that the._  ' 
national courts to which relevant questions may be referred will all reach the same 
decision '"  for example, as regards- the~  scope· of protection offered by  a~patent.. 
Consequ~ntly; the Commission's i~itial proposal. contained ·a number of definitions 
and rules of interpretation designed to clarify exactly what is patentable arid what .. 
is not, and to resolve the problems of-demarcation  ~th plant variety rights.  The 
proposal  also  contained ·provisions  whereby  patent offices  would  have·  had .  to 
. -foHow a uniform practice as  regards granting pate.nts and assessing applicati.ons. 
Lastly; tl}.e . scope· of  pr~tectiol)  conferred· by  a ··patent  for  a  biotechnological 
invention was defiried.  ·  · 
i. 
The conditions  ~e: novelty, ilwoivement of an  inventive step, and industrial application. 
The· except{ons  arc:  o;dre  public- qt morality,  plant or aniit:J.al-varieties,  and  essentially  · 
biological  proc~sses for .the production of plants or animals.·  · 
Finland will be acceding to  it very shortly:  . - .  .·  .. 
The  _first  version  of the 'Convention  for  the  European  Patent  for  the  common  market, . 
known  as_ th_c  Community  r~tent Convention. (CPC),  was  signed  in.  Luxe~  bourg  ori 
15  December 1975. It now  forffis  part of.the Agreement relating to Coniinuriity  patents~ 
concluded  in  Luxembourg  on  15  Decembe;  1989, whjch has  not );et ·enter~d. into force 
(OJ No  L 401; 30.12:1989, p.  1).  .  - .  .  . 
4 . 9.  The  initial  proposal  was,  therefore,  largely  technical  in  character.  Not that the 
ethical dimension was ignored but, at that time, it appeared that the exclusion from 
patentability  of inventions the  publication  or  exploitation  of which  would  be 
contrary  to  public  policy  or  morality,  which  was  common  to  all  . the 
Member States' legislation on patents for invention and to the EPC(7), met the need 
to take into account the ethical dimension of biotechnological inventions. Further . 
harmonization  of national  laws  did  not  appear justified, given  that  they  were 
already based on a common principle and that each case had to be assessed on its 
m~~~  .  .  .  . 
REJECfiON OF 1HE INITIAL PROPOSAL 
·1 0.  On .I  March  1995 the Europeari Parliament concluded the codecision procedure. by 
. ·rejecting  the  jpint  text,  approved  by  ·the  Conciliation  Committee  on 
23  January  1995, for  a European Parliament and Council Directive on the legal 
protection of biotechnological  inventions(
9
l.  The me.a.sure  is  thus deemed- not to 
have  been  adopted,  and  the  legal  environment  regarding  biotechnological 
inventions is  unchanged. 
THE  CURRENT SITUATION  WITH.OUT A DIRECTIVE: GREATER LEGAL-UNCERTAINTY 
l,l.  The  vote  on  l March 1995  shows  that  the  plenary  stttmg  of  the 
European Parliament. was,  ultimately,  not  able  to  accept  the  outcome  of the · 
negotiations within the ConCiliation Committee.0°l The Commission has, therefore, 
to· acknowledge that the issues raised by the legal protection of biotechnological 
inventions  have  still  not  been  resolved  in  a  sure ·and  uniform  manner  for  aU 
Member States. The legal uncertainty that constituted the justification for the 1988 
proposal remains.·  ·  · 
l2.  National  patent  offices  and  the  national  courts  may. always  refer  to  extstmg 
legislation  that  indisputably  applies  to  biotechnological  inventions.  No 
. technological  field  is  excluded  a priori  from  patentability,  provided  that  the 
conditions  governing  protection ·are  satisfied:  The  vote  on  l March  may  not, 
therefore, be interpreted as requiring a moratorium - either de jure or de facto. · 
13.  But patent law now appears even more incomplete and uncertain than in  1988, and 
it is not realistic to hope that this can always be remedied through an unambiguous 
and equitable interpretation shared by all the courts in all the Member States. The 
most important thing is to assess the ethicaLdimension of certain biotechnological 
. inventions which,  unless otherwise clarified by  the legislature, could tum 04t to 
be a Pandora's box fr.om  which emotive issues ·are constantly likely to  emerge.·  · 
14.  Matters will  not resolve themseives  With  time.  An  increasing number of patent 
applications, including in  genetic engineering, are being deposited and  granted. 
Consequently,  · there  will  be  more  and  more  questions  .to  resolve.  The 
European Patent Office~s statistics are illuminating in this respect (see Annex). 
(7) 
(8) 
.  (9) 
(10) 
Article 53(a). 
The classic example of an  invention that must be excluded on grounds of public  poh~y · 
or morality is  the letter-bomb.  · 
C4-0042/95:.. 94/0159(COD), doc  PE-CONS 3606/l/95, 21.2.95, OJ  No  C 68, 20.3.95, 
p.  26: 
See paragraphs 27 to  32 below for a summary of the joint text. 
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!  .  : 
I. 
! . , 
,I 
• 
15.  ·Reference to the'Eilropean Patent Office's activities is justified b~cause, even if-
by definition- a directiv.e hannonizirig Member States' legislation may not directly 
·.  influence the EPC  and the European Patent Office's rulings; Article 2(2) of the·.  · 
EPC states that "The Europec!n  patent shall,· in each of the Contracting States for 
which it  is granted,· have ihe effect :af and be  Sli~ject io  the same conditions as· a. 
national  patent  granted  by  that  State;  unless  otherwise·  provided  in  this.  · · 
Convention. II  Also,  Article. 13 8  of the  EPC.  states,. among· other  things,  that . 
"(1) Subject  to  the  provisions of  Article  139,  a European  patent  may  only  he 
revoked un,der the  law  of  a Contracting State,  with effect for its temtory, on the  · 
following  grounds.:  (a)  if the  suhject.:.mdtter  of the  European  patent  Is  not 
patentable within·the tenns ojA_rtic/es 52  to  57 ... "Cill_  ..  ..·  ..  ·  .  ..  ·  · 
16.  . Consequently, the  CommissL~n has been forced to acknowledge that it is no use 
believing that,  in the  abs,ence  of harmo'p.ization of  national  la~s 'on  patents for 
invention, -~he EPC  and the rulings of the European Patent Office would prove 
sufficient.  . .  .  .  . '  . 
17.  Nor qoes the case-law of the European Patent Office yet appear to be v~ry·firmly­
established, and it _will take several. more years before it can becorne.the first point 
of  ~eference02 ). ·  ·  .  ..  .  .  .  ·.  :  .  .  ·  . :  ·  ·.  ·  ··  ·  . 
. 18..  At  pre~ent; therefore, it .camiot be claimed that all  Eutopean patents  g~anted and  .. 
·entering the national stage in the designat~d Contracting States will be iJ1terpreted. 
in.  the  saine  way,  regardless  of· the  national  court involved.  Nof on:ly  must  a 
decision be taken as to whether an itfventi<ni may be patented or not~'the precise 
19. 
(II)  , 
(12) 
· scope of  the ·protection conferred by a patent must also be ascertained if  the holder 
institutes  infringement  proceedings.  In  the. absence  of. clear  reference  points, · 
. national courts may react differently.  At present, national courts are accustomed 
to  deferring judgment pending the European Patent Office's final deCisions.  But 
that will  take  ~ long time ·yet and· will  not,  ultimately; be binding on national 
courts:  the latter _will  always be (ree  ·to~ decide on the basis of the if1terpretation 
they regard as  correct.  ·  · 
As a' result of  this uncertainty arid  confusio~, some national legislatures m~y wish 
to  react  by  adopting  diffeii'ng  national  legislative. solutions.  The  objective of 
hamionizirig Member States' legislation in order to ensure the smooth functioning 
of the internal. market so as to promote a more .competitive economy could thus . ,  . , 
be.directly called into question once again° 31.  - · 
.. ,·' 
Articl~l~9 ofthe EPC. concerns rights ofcarlier d<de or the_same date. Articles 52  to  57_ 
lay  dow!}  the conditions. governing  patt~ntability. Article 53- stipulates the exceptions to 
patentability:. "Ezirope.an  paten:ts  shall. not be  gr{Qlted  in  respect of (a)  inventions :the 
publication or exploitation of which  would be  tontrary  to  "ordre  public" 0; m()_rality, 
provided that. the exploitation shall hot be deemed to  be so Cont;arymerely because it is. 
prohibited by law  or regulation jn some or all  (~[.the Contracting States;  (b}:pl{Qlt  or 
animal varieties, or essentially bir'logicaJ processes for the production o.fp[{QltS or  {Qlim afs; 
this provision does hot apply to microbio!ogical processes or the products thereof" 
For  example, on 29 July  1·995 'the President of the  EPO  referred-a point. of law to the  . 
EPO's Enlarged Board of Appeal in  order to  ensure uniform  application of.the law ·and,· 
in  particular, of Article 53(b) EPC (OJ EPO 9/95, p.  ~95). ·  .  . 
(B)  C~mmission  White  Paper  Gro'wth,  cqmpetitiveness,  ·employment,  Bulletin · EC, 
Supplement 6/93, p.  14,. Making the most of the single market. Paragraphs 35  and 36 of 
the Court of  Justice's judgment :in Case C-35,0/92, stipplementary protection certific~te fo~ 
medicinal products.  . . 
6 
..  ~~ 
.... · 20.  The Commission is ~lso obliged to note that the French legislature has introduced 
a new law:  Law No 94-653  of 29 July  1994  on respect for the human body04J. 
Article 7 of the Law 3.IJ1ends  the first two  subparagraphs of Article L 611-17 of 
the  intellectual  property  code:  "The  following  shall  not  be  patentable:· .(a) 
. Inventions  whose  publication  or-implementation  would be  contrary  to  "ordre 
public'~ or morality,  provided that the implementation of  such an invention is not 
considered  so  contrary· merely  on  the  grounds  of a  legislative  or regulatory 
provision;  consequently,  the  human  body,  its  elements  and  products  co1d 
knowledge relating to  the  overall structure of a human gene or element thereof 
may not,  as such, fonn the subject-matter of  patents." 
1iiE NEED  FOR FUR'I'HER COMMUNITY ACfiON 
21.  . 
22. 
. 23. 
24. 
25. 
(14) 
(15) 
(16) 
(I  7) 
Following the vote by the European Parliament on 1 March 1995, the objective of 
harmoniZing national  patent law - by  introducing provisions to  ensure the free 
mov~ment  of biotechnological products and the smooth functioning of  the internal 
market  - still  remains  to  be  achieved  as · regards  the  legal  protection · of 
biotechnological inventions. Thus practical shape has still not been given to this 
measure, which was  announced by  the White Paper on completing the internal 
market.  ·  ·  . 
The  observations  made  in  1988  with regard  to  the  shortcomings of the  legal 
environment for  biotechnological  inventions  are  all  the  more  valid today.  The 
evident legal  uncertainty is bound to  prevent the necessary answers being given 
to the questions now arising-with increased urgency.  -
French· Law  No  94-653  of 29 July  1994  is  a  sign  that  the  Member States' 
legislatures will  not be able to put up  with the current situation for very  much 
longer.  ·  · 
It should also  be noted that economic forecasts  regarding the world market for 
biotechnological products have become more specific and refined since the initiai 
proposal  was  published.  In  1988,  following  ·a  study  carried  out in  1986,  the 
world market by  the  year 2000  was  estimated  to  be  worth  USD 40 billion<
15
). 
According to the latest estimates, the world market in the year 2000 is valued at 
· ,ECU  83.3  billion  (see  Annex).  Accordingly;  the  Molitor  group  stresses  that: 
"The Commission should put forward as .soon as possible a new proposal for the 
- legal protection of  biotechnological inventions in order to avoid  further Increasing 
the  gap_~etween  th~ len,islative framework for investment in  th~ EU and its main 
competitive countnes" 
6>.  .  .  .  .  . · 
.  '  ' 
The  industry  that  invests  the  most  in  perfecting  new  products  based  on 
biotechnologies is the pharmaceutical industry. In this connection, the Commission · 
should mention "Council Regulation (EEC) No 1768/92 of  18  June 199i  concerning 
the creation of a supplementary protection certificate for medicinal products. The 
Regulation  is  designed  precisely  to  promote,  in  Europe,  the  long  and  costly 
research involved in perfecting medicinal products. The aim is to provide equitable 
compensation for the effective reduction. in  the protection offered by the patent, 
which  is  caused  by  granting  authorization  to  place  medicinal  products on the 
market.07
J The supplementary protection certificate for medicinal products confers 
French Official Gazette of 30 July  1994. 
COM(88) 496, op.  cit.,  paragraph 19, p.  8. 
Report  of  the  group  of  independent  experts  on  legislative  and  administrative 
simplification, Brussels, 21.6.1995, COM(95) 288 final/2, proposal 5, p.  18.  · 
OJ N<;)  L  182, 2. 7.1992, p.  1.  The fourth recital of the Regulation refers to  the present 
situation leading to ·a lack of protection which penalizes pharmaceutical  re~earch.  . 
7 • 
the same .rights as conferred by the basic patent (Article 5 ofReguiation l76S/9i)  .. 
It would be.paradoxical to accept a measure wliich, while designed to increase the 
European pharmaceutical industry's competitiveness, merely confirms a system of 
·'protection  that  - as  regards  medicinal- produ'cts  made  using  biotechn,o\ogicai 
processes  - will  become  increasingly ·unsatisfactory  unless  it  is  clarified  and 
adjusted.  ·  · 
26.  - A mimberofmedicinalproducts are indeed being produced using biotechnology 
(see  figures  quoted  in  the  Annex),  as  is  noted in  Council .Regulation  (EEC) 
·-No 2309/93 -of  22 July  1993  laying  down  Community  procedures  for·  the 
authorization and supervision'of medicinal products for human and veterinary use · 
and establishing· a Europea11 Agency  for'the Evaluation of Medicinal  Products  . 
. : Part A of the Annex to  the Regulation !ipecifically refers to  the possibility that 
certain medicinal products may be derived froin elements of the human body and  · 
point~  out .  that  some  ·biotechnological  processes  make  it m(\Ildatory  -for  the 
Corrimiinity to grant authorization· for placement on. the  market08).  -The  industry  -
therefore needs to  know to what extent it will be able to protect its investments 
. in_ perfecting new medicinal products.  ·.  ·  '  ·  · · 
I,,\  I 
.  ·- .B.  ·- -_  AssESSMENT OF nm  JOINT TEXT APPRovED-BYTIIE CoNCILIATioN coMi\.trrrn:E oN 
23  JANUARY  1995 
27.  · the  conciliation  procedu-re  was  initiated  because,  qn · i 9 September 1994, · 
the Council _  .  was  _  unable  to  accept  the . amendments  · supported  _  by  the 
_  European Parliament at second· reading<
19
).  ·  .  __ 
-~-
28.  On  23 January j 995  the  .• Conciliation  Committee  approved . a  joint  proposal. 
Discus'sion centred o_n  new wording for the tenth recital of the Council's common 
position  (vy-hich- became  the  twelfth  recital  of the_  joint text).  It  had· to  be  . 
-determined whether-the words "as such"  in point (a) of the second subp(iragraph-
(I R)  , 
(19) 
(20) 
· _  ofArticle 2(3) differentiated _sufficiently betweeri a discovery_ and an invention as 
·regards body elements of human.origin:<
2
o) "On_this basis,  the following inter alia 
!fha/1 be unpatentable: (a)  the human body or parts of  the human body as such_· ... ". 
· Eventually  a  compromise  was  reached  within  th~ Conciliation  Committee:  the 
words  "as  such" were  retainedjn the -twelfth  recital,  which  was  reworded.  But 
there  is  still  some doubt,  since the  Council·- and the  European Pariiarnent have -
made contradictory statements regarding the- interpretation of that recital.  ' 
·~  '  ~  . ' 
·OJ No L 214, 24.8.i993, p.  1.  The Annex is  ~n page 21, and Part A refers to recombinant-·-
DNA tcchn()logy, -~ontrolled expression of genes coding for biologically  acti~·c proteins 
in prokaryotes and.cukaryotes including transformed mammaiian cells, and hybridoma and 
.monoclonal  a~tibody mcthods.'Part B ofthcAnnex lists thetypcs.ofmedicinal products 
·.that  may be placed 9il the  ~arkct once the Connhissi9n has ·granted  authorization. The 
list includes new  m~dicinal products derived from· human' blood orhulnan p'Iasma.  ·  _ 
The opinion (firstreading) was deli'vered on 29:10.1992, OJ No C 305, 23.11.1992.The 
Commission presented  an  amended ~proposal on  16:12.1992, COM(92) 589 SyN 159, 
OJ No  C 44,  16.2.1993, p. 36. Tl:te  CoJ.Incil  adopted  <(common position ·on  7.2.1994 
(Common  position  (EC)  N6  4/94,  OJ  No  C  101,  9.4.1994,  p.  65).  The  Commission 
communicated  its  views  on  the  common·  position. to  the  European  Parliament  on 
17.2.199.4, SEC(94) 275 final- COQ 159. The three amendments supported by Parliament  _ 
at  the  second reading arc  included  in  Parliament's ··decision of 5.5.1994, OJ No C 205, 
-25.7.1994, p.  307.  The  Commission-'s  opinipn  on  tho~c-threc-aQtcndmcnts -is  given  in  . 
document COM(94) 245  final~ COD !59, 9.6  .. 1994.  - ·  -
See  explanatory  memoranaum.  to  _the  report. by  Parliament's  delegation- to  the 
Conciliation Committee, 23.2.1995,_-)lE 211.520/dcf. 
\. 29.  The other problem to which a solution seemed to have been found in th_e joint text 
was  the  deletion  of "automatic"  in  the  thirteenth  recital  (which  became  the 
fifteenth recital of the joint text). That recital explained the limits of the exception 
to patentability in point (b) of the second subparagraph of Article 2(3) regarding 
''processes for modifying the  genetic  identity  of the  human  being contrary  to 
human dignity". The thirteenth recital of the common position stated that, even if 
it were possible to obtain a patent fpr a process for modifying the genetic identity 
of the human being, "that  would in  no way imply automatic recognition of the 
patentability and legitimacy of  what is known as genn line gene therapy  ... ".The 
use of the adjective "automatic" could suggest that there might be non-automatic 
cases permitting recognition of the patentability. and legitimacy of what is known 
as germ line gene therapy<
21
).  .  · 
30. 
31. 
1 
The Conciliation Committee also brought point (c) of the second subparagraph of 
Article 2(3), which concerns the exclusion from patentability of  transgenic animals 
where ·certain conditions are not met,  into  line  with the fifteenth ·recital of the 
common position (which became the seventeenth recital of  the joint text). The aim 
was to incorporate into the. article itself the criterion of proportionality set out in 
the  recital,  in  order  to  assess  correctly  the  acceptability  of the  "suffering  or 
physical handicaps inflicted on  the ·animals" in relation to the substantial benefit 
represented by the invention.  ·  · 
The Commission should point out that the  crit~rion of proportionality is justified 
particularly in  view of Council Directive 86/609/EEC of 24 November 1986 oil 
the  approximation  of laws,  regulations • and  administrative  provisions  of the 
Member States regarding the protection of animals used for experimental and other 
scientific purp<?ses<
22
).  ·  .  .  .  .  ·  _  . 
32.  Lastly,  the· European  Parliament's  delegation  to  the  Conciliation  Committee· 
stressed  the  need  to  .  provide  for  a  derogation  in ·respect  cif  breeding  stock, 
analogous to that provided foi in respect of farmers in Article 12 of the common 
(21) 
(22) 
· position.  By way  of compromise,  the  Commission had proposed a  declaration 
[unofficial translation]: "Once a provision has been introduced, under Community 
law concerning. the production of animal varieties, that will enable farmers to use 
protected livestock for breeding purposes on· their own farms in order to replenish 
their stock, the Commission undertakes to take due account ofthat provision with 
a view to ipcorporating a  corr~sponding derogation into the Directive."  · 
The purpose of this  therapy  is .to  remedy  genetic changes that cause  serious  diseases, 
thereby preventing them from  being passed on to future generations (Opinion No 4 of the 
Commission's group of advisers on biotechnological ethics, "The ethical aspects of gene 
therapy").  -- . .  . 
OJ No L 3~8, IR.l2.1986, p.  I. Article 3 of the  Directive states  that:  "This  Directive 
applies  to  the  use  of animals  in  experiments  which  are  undertaken  for one  of the 
· following purposes:  . 
(a)  the  development,  m~ufacture, quality,  effectiveness and safety testing of drugs, 
foodstuffs and other substances or products,·  · 
(i)  for the avoidance, prevention, diagnosis or I realm ent of  disew;e,  ill-health or other 
abnormality or their e_ffects in man,  animals or plants; 
(ii)  . for the assessment, detection, regulation or modification of  physiological conditions· 
in man,  animals or plants;  .·  . 
(b)  the protel:lion of the ndlural env~ronment in the inhfrests of  the health or welfare 
of  man or animal." . ( 
C.  THE. LEGAL  BASIS 
33.  Since the objectives of the. present proposal are the same as those of tlie original 
19~8 proposal, namely to ensure the free movement of patented biotechnological . 
products  by  harmonizing  Member States'  laws  'so  as  to. clarify  t4e  legislative 
environment for such products, the Commission proposes retaining Article.lOOa 
of the EC  Treaty as the legal basis<
23
)_  _ _  ·  ·  - - . 
34.  In drawing up  the proposaL th~ Commission took due account of the  provision~ 
of Article 7c of the Treaty and noted that_ there is currently no need to_ lay doWn 
special provisions or to  provide for exceptions.  . . 
3  5:  Similarly, the Commission. examined the qu_estion of tl:ie  high level of protection · · 
required  with  regard  to  health; safety,  environmental  protection. and  consumer 
· protection wider A_rticle 1  00a(3) of the Treaty: In this connection the Commission . 
wishes to emphasize, in  particular, that harmonization of national laws on patents 
for invention may  b_e  carried out orily  in  accordance with a legal framework that . 
already  exists  or is  to  be  devised  concerning  health,  safety,  environmental  and 
consumer protection<
24
)_  A patent for invention does not confer the right to exploit 
(23) 
(24) 
(25) 
(26)· 
· an· invention without restriction.  A. patent merely  enables the holder to  prohibit 
third  parties  from  using  the  invention  without  authorization. ·In  terms· of  , 
competition rules,_ a  patent confers a purely negative right of exclusion and not a 
positive right of exploitation.  ·  ·  ·  " 
The proposal takes into' account the Community's international commitments and, 
in  particular;  is  compatible  with  Articles 27  and -30  of  the  Agreement  on 
trade-~el~ted aspects  of intellectual .  pr~pem;  _  rights,  ann'exec;l  to .  the_  Agreement 
estabhshmg t~e World Trade Organtzation<
2 
)_  ·  ·  · 
- '  '  ~  . .  . 
·The  _p~oposal _is  also  coinp~tible with the Convention on Biological-Diver~ity, in 
particular Arttcle  16(5)<
26
.  -··  .  '  . 
.  / 
Paragraph  59. of C<;>Urt  of Justice Opinion_ 1/94  of 15  November 1994.  Parag(aph 33  of 
Court of Justice judgment in  Case C-350/92, op.  cit. 
For example,  Di~ectivc 90/219/EEC of  23 April  1990 on the contained use of genetically 
modified.micro-organisms and Di-rective 90/220/EEC  ~f  23  April .1990 on the deliberate 
release into the environment of genetically modified organisnts (OJ No L 11-7, 8.5.1990), 
Regulation (EEC) No 2309/93 ~f  22  July 1993  laying down  Com~  unity procedures for · 
the authorization and supervision of medicinal products for human and veterinary use and  . 
establishing a European Agency for the Evaluation ofMedicinal Products (OJ No L i14, 
24.8.1993),  Directive 90/679/EEC  of 26 November 1990  on  the  protection of workers 
from  risks related to exposure to biological agents at work (OJ No L 374, 31.12.1990) as 
amended by Dircctive.93/88/EEC ofi2 October 1993  (OJ No L 268,29.10.1993)  .. · 
Council  Decision ·94/800/EC  of 22  Decem her 1994.  concerning  the  conclusion  of.  the 
agreements  reached  in  the  Uruguay  ·Round  multilateral  .negotiations  (1986-1994) 
(OJ No L  336~ 23.12.1994, p.  I).  .  , 
Council  Decision  93/626/EEC  of 25 October 1993  concerning  the  conclusion -of the 
Convention ort  Biological Diversity (OJ No L 309, 13.12.1993, p.  1).  · 
10 D.  mE MAIN  POINTS  OF mE NEW PROPOSAL 
A.  INVENTIONS AND  DISCOVERIES 
36.  The essential  aim  of the new proposal  is  to  clarify the distinction between what 
is  patentable  and  what  is  not.  In  other  words,  its  purpose  is  to  confirm  that 
discoveries  may  not  be  regarded  as  patentable  inventions.  Clarification  has 
proved necessary  following the  discussions  regarding  the  twelfth  recital  of the · 
Conciliation Committee's  joint proposal,  which  concerned  the  patentability  of 
inventions "incorporating imfustrially applicable elements obtained in a technical 
mcomer from  the human body in such a way that they can iw longer be ascribed 
to a particular individua/"(
21
).  .  . 
37.  Clearly,  on  no  account  may  harmonization  of national  laws  on  paten.ts  for  · 
invention depart from  the basic ·principles of patent law.  In order to  qualify for 
protection,  the  conditions governing patentability  - novelty,  involvement of an 
inventive step, and potential for industrial application - must be satisfied<
28
).  The 
consistent  application  of patent  law highlights  two  further  conditions  deriving  . 
directly  from  the  essential  requirement .to  comply  with  the  three  conditions · 
governing patentab\lity:. 
.38. 
39. 
(27) 
(28) 
the ·invention must be such that a person skilled in  the art can reproduce it 
(on the information contained in  the patent application), and 
the invention must be of a technical nature, in the sense that it must relate 
to  a technical  field,  must  concern  a technical  problem  and  must possess 
technical characteristics that can be set out in  the form of claims-that define 
the subject-matter for which protection is  sought. 
The patent hiw currently applicable in Europe, whether it be the Conventi.on on the 
grant of European patents (EPC) or the Member States' laws, does not define an 
invention as  such:  an  invention is identified by  reference to the conditions listed 
in the previous paragraph. However, the patent law currently applicable in Europe 
does contain a non-exhaustive list of what may not be regarded as  an  invention: 
the exclusions are either abstract in  character (e.g. discoveries, scientific theories, 
etc.),  or non-technical  (e.g.  aesthetic  creations or presentations of information). 
Thus an  invention must be both practical and technical. 
Accordingly,  as  regards. the  concept  of  a  discovery,  the  Directives  on  the 
examinations  c~rried out by the European Patent Office contain an  interpretation 
based on the consistent application of patent law in  Europe: "if a man finds .out 
· a  new  property  of a  known  material  or article,  that  is  mere  discovery  and 
unpatentable.  (f,  howeve1;  a man puts that property to practical use he has made 
an  invention  which  may  he  patentable..  For  example,  the  discovery  that  a 
particular known material is  able  to  withstand mechanical shock would not be 
patentable, hut a railway sleeper made from  thqt material could well he patentable . 
. To find a substance.fn;ely occurring in nature is also mere discovery and therefore 
unpatentable.  How ever, !! a substance found in nature has first to be isolated from 
its  surroundings  and a  process for obtaining· it is  developed,  that  process  is 
patentable.  Moreover, if  the substance can be pr,operly chmr;zcterised either by its 
strilcture,  by the process by which it is obtained or by other parameters and it is 
Doc. PE-CONS 360611/95, 21.2.1995. p.  4. 
Article  1· of the Strasbourg Convention clearly  states that:  " ...  An  inv.ention  which does . 
· not comply with these conditions shall not be the subject of a valid patent." 
II .. 
41. 
42. 
43. 
·-> 
.  'new (in the absolute sense ofhavJng  !J,O  previously recognised existenc~, then the 
·substance per·se may be patentable"C--J.  ·  .  .- ,  .  .· 
Scientific theories constitute a general instance of discovery:  for example, while 
the' physicaL theory  of semiconductivity  is  not patentable,  new semiconductor · 
devices and processes for their manufacture may well be. _ 
.  .  '  . 
To sum up, it is fair. to say that an inyention is something that provides a  technical. 
-solution to a technical problem. The technical solution may include elements that 
are  excluded from  patentability,  but that will-entail  the  whole  invention being 
- unpatentable-only where the application for-protection confines· itself to  ~lements 
. that are excluded frorri  patentability.<
30
)  The essential  factor is the technological 
contribution, given that this constitUtes the human input and that the same result 
. cannot possibly ·be achieved simply through the interplay of the laws of nature.  -
.Assessment of  the technological contribution is carried out objectively under patent 
law. The benchmark-for assessing the extent of  this contribution is the state of the 
art  as 'comprised by  "everything made_ available  to. the  public  by  means of a 
.-written or oral description,  by use,  or in any other way,  before the'date of  filing 
. of the European patent application';,.
31
).  - .  \  . 
·In accordance with the principles explained above, a element of the human bo-dy 
:that has not been obtained with. the .aid  of a_ technological  process,  but simply 
.detached, removed or collected, may not be  regarded as  a patentable" invention.  . 
Thus a limb, an ·organ or a bodily fluid (e.g. sperm, blood, tears· or sweat) caimot 
be patentable.  Regardless of whether the limb, organ or bodily  fluid ·concerned 
·ranl<:s  as  a  discovery;  the :question  arises  as  to  what  constitutes  the  technical 
solution applied to a technicat problem. Moreover, that question rriust be answered 
with reference to  the state of the art.  In this  in~tance, a sensible answer to these 
questions that refers to techn'ology is not pos,.sible.  .  · 
44:  The question as .to  the patentability of sequences of nucleotides. of human origin . 
must be understood in the light of_the above.:mentioned principles. Clearly, DNA -
which is made up of some three billion basic pairs (adenine (A) with thymine (T) 
guanine (G), with cytosine (C)) -is not patentable in its natural state in the hunian 
body, sinceit is a naturally occurring substance. But what about individual genes? 
.  - .  .  ,· 
45.  DNA is the chemical basis'for some 100. 000 genes in the genetic code. The or_der 
iri  which the basic pairs occur constitutes the gei)es'  coded information.  All. the 
genes  gather  together  in · the  form . of chromosomes  representing  the  genetic 
.inheritance of a  cell  or of a  living  organism.  That inheritance  is  passed on to 
descendent cells· and organisms:  ·  · 
46~  A cell's DNA is an inert store of information that does not renew. or destroy itself. 
(29) 
(30) 
(3 I) 
When a gene's information is to be expressed, it must first be copied in the forin 
of a  messenger  RNA  molecule.  Proteins are the  decoding  products  of these 
.RNAm's. The genetic information is expressed in the course of the line of descent_ 
from gene to RNAm to protein. Proteins are the molecules that- actually carry out 
the genes'_jnstructions.  The code that .makes it possible to determine a protein's 
structure (the "amino-acid sequence) functions according to a systelJl of_ universal 
correspondence.  This applies equally .to  bacteria and r;nammals:  one amino. acid 
corresponds to three successive ba.Ses.  Nature has selected just twenty amino acids 
as the building  bloc~s of  life, and these -are present in  allliving organisms.  · 
'  . 
Guidelines for Examination in the European Patent Office, Part c: Chapter IV, poi'nt 2.3. 
Article 52(4) EPC, which has been incorporated into legislation in  al1  the Member  St~tes. 
Article 54(2) EPC, which has been incorporated into legislation in all the Member States. 
'  ' 
·.c 
.  i 47. 
48. 
49. 
50. 
51. 
(32) 
(33) 
(34) 
(35) 
The points set out in the preceding three paragraphs are laws of nature that cannot 
possibly be covered by patent law. Beyond that, in the case of genes the question 
is  whether  the  conditions  governing  patentability  may  be  satisfied  as  regards 
certain products or processes related to the processes of life itself.  r 
The  answer  is  provided .  by  the  conditions  governing  patentability  set  out  in 
paragraph 37 and the Directive on the examination referred to in paragraph 39: if 
the  codinB. region  of a  gene  is  identified(32),  if a  process  for  obtaining  it is 
perfected<  >,  if it  can  be distinguished  by  its  structure<
34> and if this  biological 
material  provides  a  technical  solution  to  a  technical  problem<
35>,  then  it  is 
patentable. Clearly, all these operations are highly technical and can be carried out 
only in accordance with the laws·of nature applicable in the case concerned, just 
as the new-molecules that go to make up patentable medicinal products are subject 
!O the laws of organic chemistry applying to compounds of carbon. 
The state of  the art regarding DN.Ac provides an objective criterion. The additional 
DNA containing the copy of the genes' coding regions in the form  of.RNAm is 
cloned in bacteria.  Those bacteria may  constitute a genomic bank or a bank of 
DNAc. Those banks provide an accurate measure of the state of the art so that an 
assessment can be-made as to whether the conditions of novelty, involvement of 
an inventive step, and industrial application have been met. 
Accordingly,  since nucleic  acids obtained from  the human body do  not havct a 
specific technical purpose, they cannot be patented. How are the criteria inventive 
s~ep and industrial application to be applied, to the subject-matter of an application 
for  _a patent  for  invention  if there.  is  no  ready  measure  of their  extent?  An 
invention is deemed to  involve an  inventive step if "having regard to  the state of. 
the  art,  it is  not obvious to  a person skilled in the  art". ··Industrial application is 
· deemed  to  be possible  if the  invention  "can  be  made  or used in  any  kind of 
industry,  including agriculture".  If the specific technical purpose of an invention 
is not known, then these two conditions cannot be satisfied because there is no 
.state of the art against which to make an assessment.  ' 
As regards the conventional principles of patent law, there is thus no difficulty in 
distinguishing between a discovery and an invention with reference to elements of 
human origin.  Elements isolated from the human ·body by means of a technical 
process  are  artificial  and  thus  qualify  as  inventions,  since  they  are  technical 
solutions  invented  by  man  in  order  to  solve  te¥hnical  problems.  Nature  is 
incapable of producing this type of element by itself. The techniques employed in 
order to  isolate  such  elements  from  the  human  body  work  only  by  mea:ns  of 
human intervention. 
In  a gene there is  only one part that provides the  code for the  protein.  There are other 
parts  that  regulate  expression,  known  as  regulatory  or instigator regions  and  located 
·.  mainly upstream from  the coded  message~ defining the structure of the coded protein. 
With the aid of restricting enzymes and the PCR  tech~ique, enabling a specific region' of 
a whole genome to  be  detected on  the_ basis of a single cell  by  replicating  it in  large 
quantities in vitro. 
That is to say the succession.of ATGC bases determined by sequencing.  _ 
For example, if the  coded  protein  is  known,  recombinant  bacteri.a  can  be,cloned (i.e. 
bacteria carrying extraneous DNA and capable of breeding in the form of  colonies), along 
with  DNAc  (copies  of RNAm  from  cells  representing  genuinely  functional  genetic 
information)  in  order  to  obtain  a  recombinant  protein.  The  recombinant  protein  is 
artificial, as  is the DNAc taken  as  a basis. In  the case in point, the ·technical solution to 
a technical  problem  is  the  possibility of reproducing  ex vivo  a substance that nature . 
normally produces only via human beings: e.g. erythropoietine, factor VIII, etc. 
l3 • 
... 
51. 
53. 
B  •. 
54. 
55. 
(36) 
In  th~  .co~rse of the discussions  within  the Conciliati9n Committee, Parliament . · 
stressed thatthewords "as such"- the aim of which was to distinguish the natural 
elements  of  the  human  1 body  to  .  be  ex'cluded  from .  patentability - gave. the· 
.impression .of making discoverie.s patentable, which they cannot be  .. ·  A:ccordingly, 
in order .to clarify the-qaestiori of-the patentability of elements of hutmm.  origin, 
It ~s  .ssn~  ~l  t0 include'th~ words "a.S'such".in the present l)f.sal. :At 
the se:me time,: a Clari:fi£.ation has. been mel uded in order to highlight the ~ical 
possibilities offere4Lb,y  an ,invention in r.e~t  of a element of humair ·origin . 
. The·~~  llii&c~n  e~~i~~the.  d.ifference:bet~en a ~mY  ad an ... 
in,v®tion :as  Fegards·~emerits of:human origin took place against th,e ~ground 
·of interpretative guidelines as to exclusion fmm patentability on grmmds of being 
contrary to public order or public morality. But the aspects explained above m&ke 
it possible to  establish that this question of difference is  a technical  one. Thus 
patent law may not, in itself, affeCt the fundamental principle excluding all rights  .· 
of  ownership in  respect  of  .the.}:luman being. A gene or a cell, in their natural state; · 
must b~ excluded from patentabilitY be.cause they cannot be regarded as patentable 
inventions. 'In this respect, 'patent law does not have to adopt an ethical stance for . 
reasons of public policy or morality.11 has-only to observe its own principles. In 
·the Commission's view, in the interests of clarity the rule .of law r~lating to  this 
· question of·excluding from patentability elements of the human body that cannof 
be regarded as inventions should betackled within a mote appropriateframework 
Thus the  convention~l system. of patent law established by the  laws of all  the· . 
Member States and by· the EPC .will  b~ observed.  .  ·  .  .  ·  . 
A CLEAR EXCWSION FROM PATENTABILITY OF GERM LINE GENE 1HERAPY ON HuMANS  '.  .  .  .  . .. 
Poin~ (b)  of  the·  second  subparagraph-·  of  Article ~(3)  of· the  Conciliation 
Committee's joint text .excluded from patentability  "processesfol~ mod{fying the 
genetic identity of the  hu,man  bei11g conirary  to  human  dignity'~:  Two criticisms 
·were made of this Article.  Firstly, it was considered thaf it would introduce an 
. exception to the exclusion provided for by. Article 52(4) of the EPC, under which 
.·.methods for treatment of the human  or animal  body by surgery or therapy  and 
diagnostic. methods practised on the human or aninial body are not to be reg~rded 
as inventions which are susceptible of industrial application.  Secondly, the article 
was diticized for not adopting a clear $tance on principle against germ liny gene 
~~- . 
As regards this  pos~tion of principle against genrt line gene therapy that should 
have  been or should  be  ta:Ken  when  harmonizing national  laws  on  patents  for 
invention  in  respect  of biotechnological  inventions,  the  Commission· can .only 
-emphasize .that patent law cannot allow itself to  adopt  a  position on  principle 
erga omne~·.  Two important recent "statements by  CQmmittees on ethics serve to 
stress the complexity of the issue and tQe  difficulty of tal<ing  a final  decisionc
36
J. 
While it may  not be  possible to  adopt  :.'!11  ethical  stance .on prin-ciple  that may 
extend beyond the scope of  a directive harmonizing legislation on biotechnological 
inventions, 'there is no doubt that the present proposal may clearly exclude from 
. patentability germ line gene therapy on humans.  :  ·  · 
·.--· 
.  .  .  '  •. 
Opinion No 4 of  the Commission's group of advisers on biotechnological ethics, regarding· 
.ethical 'aspects  of gene therapy,  and  the  August  1994  report- by  the .sub  ... comm ittec  on. 
humari  gene .therapy  of  the  UNESCO  International  Bioeth~cs Contmittee,  conce~lng 
thcrapeut(c applications· of  genetic'_~nginecring.  · 
·14' C.  FARMER'S PRIVILEGE AS REGARDS BREEDING STOCK 
56. .  The Conciliation Committee's joint text did not provide for the direct introduction 
into patent law of farmer's privilege as regards breeding stock:  it referred to the 
future  introduction  of Community  legislation  on  animal  variety  rights,  which 
would  include  a  . derogation  similar  to  that  contained  in  Article  14  of· 
·  ·  Col.mcil Regulation (EC) No 2100/94 of  2 7 July  1994 on Community plant variety 
·  · rightsc
37
J_  Consequently, when the time came the Commission. would have been in 
a position to propose a' specific derogation to  be incorporated into legislation 9n 
patents for invention, as had been done for the product of a harvest in Article 12 
of the Conciliation Committee's joint text. 
57.  To  clarify the situation, the Commission proposes that preferential treatment fqr 
farmers in respect of breeding stock be introduced directly into patent law. 
D.  NEW  PRESENTATION 
58.  In order to make the proposal for a Directive clearer, ·it seems appropriate to atter 
its structure. Definitions are now given at the beginning of the text, followed by 
provisions on patentability.  In  accordance  with the  structure of Member States' 
legislation and the EPC, .the first description given is of what may not be regarded 
as a patentable invention. The extent of, and exclusions from, patentability are then 
specified.  Finally,  exclusion  from  patentability  on grounds of public policy  or 
morality is clarified.  · 
llL  EXAMINATION OF THE PROVISIONS 
. Article 1· 
59.  This· Article now comprises ·two. paragraphs. 
The first is  taken over from Article  1 of the Conciliation Committee's joint text 
(referred to below simply as·the joint text)c
38
). It states that the proposal fits into 
the existing framework of legislation on patents for invention and is not int~nded 
to introduce patent law applying specifically to living matter. 
The second is taken over from ArtiCle  18 of the joint text. It ·seems appropriate to 
point out at the beginning of the  proposal  that patent law may  on· no  account 
depart from the general common law on monitoring the applications of research 
and exploitation or the commercialization of its results. 
Article 2 
60.  This .Article is new and not taken over directly from the· joint text. 
(37) 
(38) 
It contains three definitions. 
The first defines biological rnaterial as any material containing genetic information 
that is self-reproducible or reproducible within a biological system. This is taken 
over from Article 2(2) of the joint text. 
OJ No  L 227,  1.9.1994; p.  I. 
Doc. PE-CONS 3606/l/95, 21.2.1995. 
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61. 
.. 
:  ··~. 
The  secpnd  defines  a  microbiological  proces·s  as  any  process involving  or 
. performed upon· or resulting in  microbiological material.  A process consisting ·of 
a successiolrof steps is to  be treated. as  a microbiological process if at least one 
. essential step of  the process· is  microbiologicaL This definition is taken from the: 
second·  sentence  of  Article 5( I)  and  from · Article  5.(2)  of  the  joint  text. . 
Microbiological  material, -therefore,. means  any  biological  material made  up  of 
micro-organisms or .cellular or subcellular bi()logical material derive_d from plants, 
animals· or the human body.  · 
The third  d~fines, an  essentially biological process _for the production of plants or 
.  ~imals as  any  process .which, taken as  a whole, eX:ists·in  nature or is not more 
than  a natural  plant or animal  breeding process.  This defin,ition  is  based on the 
third sentence of Article 6 of  the j~int text.  - .  ··  ·  :  . · 
Article 3. 
This Article comprises two paragraphs. ·' 
The first stipulates that the human body.and its elements ·in their natural state  an~. 
not to be  considered  patentable  inventions.  It  places  point  (a)  of  .. the  ~econd 
subparagraph of Article 2(3) of the join.t text in  a: technical context. Article 3 of·  , 
tQe proposal :Is thus intended to fit in with the. conventional 5ystem of patent hiw.  .  .  - .  .  .  -- .. 
The words· "as such",  which ·gave rise to the  diffi~ulty in interpretation 'regarding 
the distinction between a di~covery and ah 'invention in relation to' elements of the 
human body, have not been  included~  ·  . .  / 
The first  p~agraph states that '.'The -h~unan  ·body and its elements in their nat~1rol 
state arenot to be consideredpatentable irtventio'i1s:nThe phrase)n italics draws· 
the distinction between a discovery ·and an invention. As already explained above -
(paragraph 51), patentability-applies to something that is artificial in the sense that " 
it is a technical solution to  a technical problem  and has been  invented_ by  man. 
Conversely,  a discovery  concerns something natural .. The need· to -draw  a  clear 
distinction provides the justification. for  referring; in  the second paragraph, to. a 
technical· process in contrast to  what is natural.  Thus the words "in their natural 
state"·  are  used to·  stress. that elements of the human body -are  to  be treated  as 
. discoveries and not to be considered as inventions.  ·  · 
The second paragraph stipulatesthat biological material of  human origin may form 
the· subject-matter of an. invention  .. 
/  1Jlis provision is necessary in order to make clear that elements of human .origin . 
must satisfy the conditions governing patentability before they can be considered 
inventions.  ·  ·  ·  ··  ·  ·  · 
.  .  .  .  .  .·.  '  '  ...  '  .  .  . 
· The ~le~rest  way of highlighting the 'requirement for there to be an  i~vention is to  · · 
stress the fundamental_ principle of patent Jaw:  in  order to qualify for protection~ · 
the subject-matter must constitute a technical solution to a technical problem. It 
. thus-proves essentiat to· stress the industrial application requirement. All technical 
activity  is  covered,  since · patent  law· defines  the  condition  as  follows:  "An 
·  invention ·shall be considered as s'usceptible of industrial application if  it can  be. 
- made or used in any. kind of  industry: including agriculture."  -. ·  · ··  .  ·  · 
The industrial application of an  in~enf!on is specified in the description  th~t  must 
he  submitted  when  the ·patent  application  is  filed .. The  description. must  be 
S\lfficiently clear and comprehensive for someone skilled in the aq to be able to 
cairy it out. ·Accordingly, it must: - - .  -
.specify the _technical  field to. which the i11vention rdates; 
;  -\  '  .. indicate the previous State of the art; 
explain the invention such that the technical problem and the solution can 
be tinderstood; 
specify in detail at least one  ~way of making or doing the thing_ invented. 
Des~riptions of m.tcleotide and amino-acid sequences· in patent applications have 
now been standardized under World Intellectual Property Organization (WIPO) 
standard ST.23<
39
).  ·  -
. ·There is thus no problem in affirming that patent law places.at the disposal of all 
interested parties the scientific information  relating to the  invention.· All  patent 
applications  are  published.  Consequently,  obtaining  a patent can  in  no  way  be 
..  taken  as  indicative of a wish to  stifle research. ·Patentlaw is  absoh.1tely  clear on -
this point,  since it states that it does  not  extend to  "acts  done for experimenial 
purposes relating to  the  subject-matter of the patented invention'K
40
) . .  - -
An  element of human  origin ·that  is  capable ·of industrial  application  must be 
"isolated from  the  human body or otheJWise produced by means-of a technical 
_ process".  This form  of words has  been  chosen in  order to  show,  as  clearly  as 
possible, that  the patentable element is no longer in its natural state in ·the human 
~ody.<
41 ) It is the result of an  ¥fificial process.  ·  '  . 
The  restricting  enzymes  technique,  which  enables  a nucleotide sequence  to  be 
isolated from the genetic code, and ACP, which· enables a nucleotide sequence to 
be replicated in vitro in a large quantity, can work only after human intervention.· 
The wording "isolated from  the human body or otheJWise produced-by means of 
a  technical  process"  should  therefore  be- taken· in the  context  of these  two 
techniques.  ·  · 
-The second paragraph ends with the words "even if  the structure of  that element 
is identical to  that of  a natural element".  This wording is taken from the twelfth 
recital  of the  joint  text,  and  was  suggested  by  Parliament's -delegation  to  the 
Conciliation- Committee. It needs  to  be  included  in  the  main  body  of the text  -
because the  chemical  structure of an ·element isolated from  the human body by 
-means of a technical  process that may  form  the subject-matter of an  invention 
capable of  industrial application might be identical to the chemical structure of the· 
element such as it occurs naturally inside the human body.· This is so in the case 
of enzymes, for example, 
A.rticle 4 
62.  _The  first  paragraph .is  :based  on  Article  2(1)  of the joint text,  and  states  that 
(39) 
(40) 
(41) 
biological material is patentable.  · 
. .  .  . 
The second paragraph is based on Article 3 of  the joint text. It confirms that plants 
and animals and elements theroof are to be patentable as biological materiat There 
is one exception, however: plant and animal varieties as such, in accordance with 
Article 53(b) of the EPC. 
. -' 
Supplement No  2 to  EP'O  Official Journal No  12/1992. 
Article  27(b)  of the  Luxembourg  Agreement  relating  to  Community  patent~:  The· 
Agreement  has  not yet entered  into  force,  but  this  Article has  been  incorporated· into 
legislation in all the Member States.  -
See earlier in paragraph 6 1  . 
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A i1icle  5. 
63.  This Article is  based on  the _first  sentence of Article 5 of the joint teJrt.  It states  · , 
that microbiological processes  all~ products obtained by .~eans of such processes · 
are to b.e  patentable.  The latter point was not included in the joint text, but it is . 
64. 
. helpful  to follow the  word,ing  of Article  53(b)  of the  EPC. (which  has  been  . 
·  :incorporated  into~ l~gislation in _all  the Memb~r  States)  .. :  · 
A rtic/((6 
This is  based on  the first senteri¢e of Atiicle~ 6 of the joint text,· and states that 
essentially biological processes for. the production of plants or animals are riot to 
~e  paten~able.  · ·  ·  ·  ·  ·  · 
Article f' 
i 
. .  ·~  . 
· 65 ..  · · This is based on Article  ~. of the joint  text 
It  state,s that uses:of  plant-~r animal varieties arid  proc~sses for their }>toduction, . 
other tl,.an essentially biological processes for the production of plants or: animals, .  · 
· ·'  • are to. bep~t¢ntable,  .·  ·  ·  · ·  · 
·· Aiticle '8  ·.  :  . .  . 
66. · •  ·  This is h,asC?d on Article ?of  the joint text. 
- ' 
:It states thatihe subject-matter of an invention concemitig a biological material is 
not  .to. be considered a discovery or lacking in novelty merely o:n the. grounds tl}at 
it formed part of a naturally existing materiaL This Article merely emphasizes the 
need for an  invention to  be: a technical solution to _a  technicafpro}Jlem  ..  In order. · 
not  to . be  regarded  as  a  discovery- (see  paragraph  32 · of· this· Explanatory· 
Memorandum) or as  lacking novelty, "it·must constitute  a:  technical  advance: The. 
inventi"on  may  be ba.Sed  on  something .that  already  existed  in  nature  which  it 
transfor~s. and distinguishes.·  · 
'  A i1icle 9  '·. 
67.  This is based oil points.(b) and (c) of the second subparagraph of Article" 2(3) of 
· the joint text:  · 
It ccmce~s exclusions from patentability on g"rounds of publ(c policy or morality .. 
Theaim is to establish two general guidelines (rather thailthree,.a.Sthere were in 
the joint ~ext - see paragraph  53)  on which tp  base future interpretations. of  thi~ 
possibility for exclusion. Such interpretation should be a genuine reflection of the 
ethical dimension of biotechnological inven!ions.  ·  · 
Point (a) ·restates,  in  simplified form,  po.int  (b) 'of the  second  subparagraph of 
. Article 2(3) of  the joint text. 
Its purpose is to refl_ect the. detailed. discussions· held on the scope of the joint text 
as  regards  the •  exclusion· from  patentability  of ·processes  that  alter  the  genetic· 
identity of human beings;  ·  · 
To that end, it is prop.osed to exClude ·directly from patentability "n1ethods of  germ 
line _gene  therapy 'on hum'ans," i.e.  therapy  that  could  alter  reproductive  cells 
capable of transmitting gen'etic material to descendants,  · 
Point (b) is identical to point (c)  ofthe second s~bparagraph of Article 2(3) of  .the· 
joint text. 
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68.  This is  based on Article 9 of  th~ joint text. 
The  first  paragraph  stipulates  that  the  protection  conferred  by  a  patent  on  a 
biological material possessing; as a result of the invention, specific characteristics 
is  to  eXtend  to  any  biological  material  derived -from  that  biological  material 
through  multiplication  or  propagation  in  an  identical  or· different  form  and 
possessing the same characteristics.  · 
The  second  paragraph  provides  for  the same  extent of protection  as  regards  a 
-process enabling a biological material to be produced possessing, as a result of the 
invention, specific characteristics. 
A rtic/e  11 
69.  This is based on Article  I 0 of the joint text. 
It  states  that  the  protection  conferred  by  a  patent  ~n a  product containing  or 
consisting of genetic information is to extend to all  material in which the product 
is incorporated and in which the genetic information is contained and expressed. 
It  should  be  noted  at  this . point  that  the  concept  of  genetic  information 
automatically  makes  reference  to  a  material  substratum  on  which  it  is  based, 
namely deoxyribonucleic acid.  The order in which the four bases A T G C occur 
constitutes the genes' coded information. Such information cannot be considered 
· · to be the same as the scientific information contained,· fo'r  example, in scientific 
publications.  But the  dissemination of knowledge  through the  publication of a 
patent application contributes to the expansion of scientific knowledge concerning 
.  biotechnology.  ·  · 
Article 12 
70.  This is based on  Article  ll of the joint text. 
It states that the protection referred to  in  Articles. 10  and  11  is  not to  extend to 
biological material obtained from the multiplication or propagation of biological 
material marketed in  the territory of a Member State by  the holder of the patent 
or with his consent, if the multiplication or propagation necessarily results from · 
the application for which the biological material was marketed, provided that the 
obtained material is not subsequently used for other multiplication or propagation  . 
. Article 13 
71.  The first paragraph is based on Article  12 of the joint text. 
It provides for a derogation from Articles  10 and  11  as regards the scope of the 
protection conferred by a  patent on a biotechnological invention. 
The derogation  concerns the sale,  to  farmers,  of patented propagating material. 
Farmers  are  authorized  to  use  the  product  of their  harvests  for  propagating 
purposes  on  their  own  farms.  The  scope of.  this  derogation  and  detailed  rules  . 
governing it are 'confined to those of the corresponding Community plant variety -
rights, i.e.  Article  14 of Regulation (EC) No  2100/94 of 27 July  1994. 
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The second paragraph· is new. 
It introduc_es  a derogation. from  Articles  10  and  11  in  respect .of. th~ sale,  to 
·.fariners,  of patented breeding ·stock .. Farmers are to  be  authorized  to .  use  the 
protected livestock for breeding purposes on their own farms, in order to replenish 
their 11umbers·.  - ,  ·  ·  · 
The third paragraph. is ·also. ne:w. 
.  .  ; .  .  . . 
. It concerns the extent  an~  the crinditions of tlle derogation in respect of ~·reidirig . 
. stock. Since there are, as yetj no specific Community provisions concerning ~imal 
variety  rights, the extent and conditions· are·to be determined by .national law~,•­
regulations and practices._ . 
Article 14 
• ,72,  This isb~ed on Article  13 of  the.jo~nt text.  · 
-~  It. introduces  a system. of. compulsory · cross-Hcensing  where  a  -br~eder- cann~t 
acquire Or exploit. a variety right Without infringing. a prior patent, and vice versa.  .  '  .  .  .  .  \  - -· 
_Two •  conditions· have  to  be ·met ·when .  submitting  a licence  application· to  the 
--· C()inpetent:authority in the-Member State con:cerned: 
the  applicant  must  demonstr(lte  that he has applied  un::;u~cessfully tq  the 
holder of the  patent or of the  pla.I}t  variety  right to  obtain  a  contractual 
·  licence, and  ·  .  '  .  - .  .  -
that expl'oitation of the_ plant ~ariety or. the. irtvention constitutes. significant 
technical progress.  ·  _.  ·  •- ·  __ -.  , · ·  , ·  - - ··  --~- ·  -·  ·  ·  _  .  · _  - ., 
ArtiCle 15, 
.  .  .  .  . 
73.  ,This is based on Article 14  of·the joi~t text:-· 
74. 
It  concerns  the  deposit  of,  and  access to,  a  biological .  material which  is not . ·. 
.  available to( the public .and  which cannot be des9ribed  ~n a patent application in 
·'sue}) a manner as to enable the invention to be  reproduced~by a person skilledjri 
the art.  ·  ·  ·  ·  ·- '  ·  · 
.  ' 
In this .case, the written description of the  irivention~must be supplemented by  a·_ 
physical ·component accessible atJeast to  the international depositary  authorities---
· which-,acquired  this  status  by  _virtue  of Article  7.  of the  Budapest  Treaty _of 
28  April_1977 on· the International Recognition of  the Deposit of  Micro-organisms 
for the Purposes of Patent Procedure.  ··  ·  ·  · 
- '  .  '  -:-
At 15  ApnP 1-995,  35  c~untries were party to the BudapestTreaty, including 12 
Member States  (Ireland;  ·Luxembourg  and  Port_ugal  are  not- yet party  -to  it).: 
Recognition has been accorded ·to 28 international depositary authorities, .including 
12 in the Member States.  -
Article-16 
This is  based on_ Article  IS  of  the joint text. 
It concerns the re-deposit ef a biological -rn:~teri~ which  ceas~s  -to  be ,available 
frem the recogn.ized depositary insti-tution,  either becai:tse that institution has lost . 
its  ~tatus or because the. ·biological- material i$ no 'longer "live"...  .  .  . . .  ·.·  ·  ... 
.  ..  .  ...  - - .•  .  .  . 
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75..  This is based on Article 16 ofthe joint text. 
it confirms that, if the subject.:. matter of a patent is a process for obtaining a new 
product,  the  reversal  qf the  burden  of proof also  applies  to  biotechnological 
inventions. 
Anyone other than the holder of the patent will be required to  pro~e that he has · 
Iiot made the new product  by means of 'the  patented process.  . 
. The principle of rev~rsal of the. burden of proof is  set out in  Article  3 5 of the · 
Community Patent Convention and· must be regarded as a· fundamental principle 
of European patent law on which the Directive has to be bas_ed. 
A'rticle  18 
76.  This. is based on Article  19 of the joint text. 
. It'  is  the  standard  firial  provision  regarding  the · bringing  into  force,  by 
Member States, of the laws,  regulations and administrative provisions necessary 
-to comply .with the Directive. The deadline for doing so will be stipulated at the . 
appropriate stage.  ·  · 
-Article 19 
.  . 
77.  This is based on Article20 of the joint text. 
It states that the Directive is to enter into force on the day of its publica#on iinhe . 
~Official Journal of the European Communities, in accordance with Article 191  of 
the Treaty.  ·  ·  ·  ·' · 
Article 20 
78.  This is based on Article 21  of the joint text. 
·.  It states that the Directive is addressed to the Member States. 
79.  Article 8 o(the joint text has not been incorporated into the draft prop~sal. 
. It·  concerned the· patentability of processes comprising a. succession of steps, m1e  . 
or more of which involve a .method of  treatment of the animal body by surgery or 
therapy or a diagnostic method practised on the animal. body. 
The  original  purpose  of-this  Article  was  to  provide  for· \rery  specific  cases 
involving the 'transfer of embryos between animals. It has since become clear that 
this is not a biotechnological problem. 
· 80.  Nor· has Article  17 of the joint text been-incorporated. 
It-laid down _transitional provisions regarding the derogation ·in respect of the sale, 
to a farmer, of propagating material by· the holder of a patent or with his consent.· · 
. The transitional arrangements have since been superseded by  the full  entry into 
force, on 27 April  1995, of Co.uhcil Regulation (EC) No 2100/94 on Community 
plant variety r,ights. 
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ANNEX. 
INFORMATION .ON  THE INDUSTRIES USING BIOTECHNOLOGY 
"  Whilethe.actual economic prospects of  the biotechnology product market lrave not 
immediately matched the hopes pinned on the industrial openings for _applications 
of this new technolo!:,ry,  the forecasts for the year 20_00  show  die market  re~tlly 
taking off (see following table in  billions of ecus, source:  CEFIC-SAGB, 1994):  _  .  .  . 
Medicinal  Chemicals  Agriculture &  Environment  Plant  Total 
> 
products  foodstuff.'! 
Cunent  1.2  0.1  2.4  0.4  1.0_  5.1 
( 
mad<et 
Market in  23.9.  .14.6  40.0  2  2.8·  83.3 
2000  .  --
•  The. data available for the medicinal products sector make it possible to assess rilore 
accurately the position of  European firms compared with their competitors from the' 
United  _States  and · Japan.  The  0  following  table - lists  the  world's  top . 15 
~'biopharmaceutical"  firms  by_  tUrnover- generated·  from. ·medicinal  products-
nianufactun;d using biotechnologic~ processes and products under licenc~- (squrce: 
Datamonitor, 1994): .  ·  · 
,-Company·  1993 sales  - 1993 sales 
(own products)  (+products urider licence). 
$  millions  $  millions 
Amgen  1 ·306  . 2 208 
Eli Lilly  830  - 896  . 
Novo Nordisk  797  1 003 
J&J  625'  . 625. 
-
Schering-Piough  c  597  - 597 
S-B  479  479 
Genente~h  457  1 773 
Chugai  404  404 
Sankyo  -377- .  377  -
Pharmacia- 336  336 
Merck & Co  290 
._ 
290  . 
-Roche  250  250 
Ares-Serono  '  199  - 199 
_  Genzyme  125  125 
Hoechst  121  121  - -. 
As can be seen from .the above table,. seven. US  firms  are among the top  15,  with four 
among the top five:  Amgen, Eli Lilly, J&J, Schering-Plough, Genentech, Merck &  Co, 
and Genzyme.  ·  ·  .- · 
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.  ..~  ' The  six  European firms  are  Novo  Nordisk,  S-B,  Pharmacia,  Roche,  Ares-Serano  and 
Hoechst.  · 
Two Japanese firms are listed: ·chugai and Sankyo: 
•  The. following table  showing the  number of entities involved at the  clinical. and 
post-clinical  development stages in the  fields of biotechnology and immunology 
highlights  the  lead  that  the  United  States  has  over  the  rest. of  the  world 
(so_urce:  Heinz Redwood, 1993): 
Origin  No.· of entities  No. of entities 
(clinical stage)  (post-clinical stage) 
United States ·  101  29 
Japan  12  16 
Europe  46  10 
Other  16  6 
Total  175  61 
Expressed in percentages, the  pi~ture is as follows:. 
y  .. 
Oaigiri  No. of entities  - '  No. of entities 
(clinical stage)  (post-clinical stage) 
United States  58%'  48% 
Japan  7%  26% 
Euro_pe  26%  16% 
Other·  9%  10%  ..  ·:Total  100%  100% 
•  The above figures show the leading position held by the United States.  .A  similar 
picture emerges if we look at the European Patent Office (EPO)'s figures for the 
nu~ber of biotechnology  patent applications it received and the number of such 
patents it granted between 1990 and 1994: 
23 Applications for a European patent in the. field of biotechnology: 
Origin  ·  '1990  .1991  1992  1993  1994 ·  ..  .Total 
EPO  .176  199  266  231 
'  247  U19 
member 
countries 
..  . 
'  ' 
Japan  75  73  73  59  69  349 
United  146  195  219  342.  262.  ·'  1164  J 
States. 
Other  30  -.23  40'  49  42  184 
Total  :427'  490  .,  598'  681  620  . 2816 
Expressed in percentages: 
Et~rope .  U  ni(e~ States  Japan  Other· 
39.7%  41.3%  12.4%  6.6% 
The aggregate  percentages  for  all  fields  of technology  over  the  same. period  are  as . 
follows: 
Eu~pe  lJ nited 'States.  Japan  .  Other 
48.60%  28%  19.40%  4% 
E  te  urope_an _  pa  nts grante  d  .  th  fi ld  f  b"  h  I  m  e  re  0  rotec  no ogy: 
Origin  '1990  1991  1992  1993  1994  Total 
EPO·  36  .  44  54  93  106  . '333 
. member 
countries 
'Japan  33  41  41  .46  40  201 
United  38  .  62  77  76.  114  367 
States  ._.,I 
Other  1  3  5  .  8  11  28 
Total  108  150  177  '223  271  929 
Europe  lJnited  Sta~s  Japan  ·Other . 
35.8%  39.5% .  21.6%  '3.1%  .. The  aggregate  percentages  for  all  fields  of technology  over  the  same  period  are  as 
follows: 
.Europe  United States  Japan  Other 
54.2%  23%  19.8%  3% 
The above· figures show that United States firms have a much ·stronger presence on.  the 
Eur.opean biotechnology market than in all other fields of technology. 
•  As regards European firms' presence on the United States market, a study published 
in March 1995 by Pharmaceutical Research and Manufacturers of America entitled 
"Biotechnology drug research has come of age"  states that  140 patents relating to 
genetic-engineering medicinal products were granted by the United States Patent and 
Trade Mark Office in  1994.  The breakdown of those patents by country of origin 
was as follows: 
United States  Europe  Japan  OCher  Total 
109  16  tO  5  140 
/ 
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·  .·  .  .  ·  Propo~al for a  .  .  .  .  . 
EUROPEAN PARLIAMENT AND COUNCIL DlRI~CTIVE 
'·  (lil  th~ leg;!  protcdl~nof  biotechnqi()gital iiwen'tions ,·  ·•· 
-----· 
THE EUROPEAN pARLIAMENT AND THE COuNCIL OF THE EUROPEAN lJ.NION,  ;  .· 
. Having· regard  to  th;e  Treaty  establishing  the :European  Community,  ·a.nd  In_ particular.: 
·Article 1  ~Oa thereof,  , . 
·  . f!avi~g regard to the propo~al from the Commission(!>; 
Having regard· to the Opi~ionr of the Economic:and Social Corrm1ittee<
2
); 
.  - . '  . .  .  '  ~ 
'  •"·'. 
· ·  A~::ti~g il)  ac~orda~ce with the  pr~cedure laid down in Article 'i 89b of the TreatyP1, 
(I)·  Wherea~  biotechnol9gy and  genetic engineering are pl~ying an  increasingly important 
role. irt  a- broad  .range ·of .industries  and  the  protection  of  biotechnological 
inventi9ns will  · certainly  be  of  fundamental  importance  for  the  Community's 
.industrial development; 
(2)' 
{3) 
(4) 
'  (5) 
Whereas. the investments required in research and d(weloptrient, particularly for gen.etic  · 
engineenng, are especiaUy high and especially risky and the  .possibility. of  recouping 
that invest#lent can only effective,ly be: guaranteed through adequate legal protection;' 
-.Whereas without effective and.,harmonized protection throughout the Mei:nberStates .. 
such 'investments might well not be made;  '  . 
. Whereas following. the European.Parliament's rejection ofthe joint text, approved by. 
-·the Conciliation Corrunittee, for a· European Parliament and Council-Dir~ctive on the · 
legal  protection  ofbiotechnological  inventions<
4
),  the European .Parliament arid>the. 
Council  have  determined  that the  legal  protection· of biotechnological  inventions 
.  .  .. .  '  ·.  .  ":'  .  .  .  '  ' 
cannot he left: as .it currently stands; 
When!as differences exist in the legal  protection ofbioteciuiological inventions offered · 
by the laws ahd practices of  the Member States; whereas such differen~s could create' 
barriers to trade and to th~ proper functioning of the· internal market;· 
(6)  .  Whereas·  such  differences ' in )egal protection · could  well  become  greater  ~s 
·. Member States adopt ne~  and differCilt legfslation and  'fidministrativ~· practices, or- as 
. national case law interpreting. such, legislation develops differently; 
, "  <I>  OJ No C 
.<2>.  _OJNo C 
.(3) 
(4)  ·,oJ  No c  68,  20.3.1995, p.  26.  · 
.  .  \  .  . · (7)  Whereas  the  uncoordinated dcvelopmcfll of national  laws  on  the  legal  pr(lte~t.ion of· 
biotechnological  inventions  in  the  CommunitY  could  result  in  the  creation of new 
·.disincentives 'to. trade,  to  the  detriment  of· the  industrial  development  of  such 
inventions and of  the smooth operation of the internal  market~  ·  · 
(8)  Whereas the l'egal  protection of biotechnological inventions does not necessitate the 
creation of a separate body of  law in place of  the rules of national patent law; whereas 
the rules of national  patent law remain the essential basis for the legal protection of 
~biotechnological inverition.s;  whereas, however, they must be adapted or added to :in 
certaiJ:l specific respects in order to take full  account of technological  developments 
inv6lvingbiological material which  also fulfil the requirements for patentability;  · 
(9)  Whereas  harmonization  of the  laws  of the Member States. is  necessary to Clarif'y 
certain concepts in national laws originating in certain international patent and plant 
variety· conventions  which  have  led  to  some  uncertainty  as  to  the  possibility , of 
protecting  biotechnological  inventions  concerning  plant  matter  and  certain 
microbiological inventions, concepts such as the exclusion from patentabi1ity Qf plant.  ' 
and animal varieties and of  essentially biological processes for the production of plants 
and animals; 
(10) . 
(11) 
Whereas  the  Community's  legal  framework  for the  protection  of biotechnological 
inventions  can  be  limited  to  laying  down  certain 'principles  as  they  apply ·to  the 
patentability  of biological  material  as  such - such  principles  being·  interided  in 
particular to determine the difference between inventions and discoveries with regard 
to the ·patentability of certain elements of human origin - and can be further limited 
to defining the scope of the 'protection  accorded ·by a  patent on a biotechnological 
invention, to the right to use a deposit mechanism iii addition to written descriptions, 
· to a reversal  of the burden  of proof and to the  option  of obtaining .  non.,.exdusive 
compulsory  licences ·in· respect  ·of· interdependence  between  plant . varieties 
and inventions; 
Whereas .  a  patent' for  invention  does  not  authorize  the  holder  t~ implement  that 
invention,  but  merely  entitles ·him  to  prohibit ·third parties  from  exploiting ii for 
industrial  and. C()mmercial  purposes;  whereas,  consequently,  substantive  patent  law 
cannot serve to call into question national and Community. law on  the monitoring of 
research and of the use or commercialization of its resuits, notably from the point of 
view of the requirements of public health,  safety,  environmental  protection, animal  . 
welfare,  the  preservation · of · genetic ' diversity  and  compliance  with  certain 
ethical ,standards;  ·  · 
(12)  Whereas  no  prohibition  or  exclusion  exists  in  national  or European  patent  law 
(Munich Convention) ~hich precludes a priori the patentability. of biological matter; 
. (13)  Whereas it should be specified that knowledge relating to the human body _and to its 
. elements in their, natural state falls within the realm of scientific diseovery and may 
not, therefore, be regarded as patentable inventions; whereas it follows from this that 
substantive  patent  law  lS .  not. capable  of prejudicing  the  basic  ethical  principle 
excluding all  ownership of human beings;·  ·  · 
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'  {14)  Whereas  sig~ificant 'progress  it:~  the  treatment -of  diseases  has  already- been -made 
thanks to medicinal  products derived or otherwise produced from  elements isolated 
froni  th~ human  body, 'and  medicinal  products  resul.ting  from  a  technical  process 
aimed  at 'obtaining elements  similar  in  structure  to  those  existing  naturally  in  the 
.  _~human body  and  whereas,  consequently, the  .. patent system  should .promote research' 
aim~d at obtainiflg such elerl1ents;  - ·  · 
(15).  Whereas,  therefore,  it should -be  made dear,that an i_nventiort  cap.ableof industnal 
a,pplication  and  based  on an element  isolated from  the  human  body .  or  otherwise 
produced :by  mean~  of a technical process is  patentable, everi where the structure ·oL 
- that  element  is- identical  to  that of a  natural  element,  since  no  patent  may  be 
interpreted--as  covering  an  element of the' humari  body  in -its  natural  environment 
forming the basic subject of the invention; 
( l6)  Whereas such an  element isolated, from the-human body or otherwise produced may · 
r10tbe_ regarded as unpatentablein the same way as an element of the human body  in 
its natural  st~te, that is to say, inay not be equated with a discovery, since the element 
·isolated is the ·result of the technical processes used to identify, purify -and classify it 
and to reproduce it outside the hurnan body, techniques which human beings alone are 
· capable  of putting  into.  practice  and  which  Nature  is  incapable  of accomplishing 
by itself;  -. 
.  ·.  ·  ( 17)  Whereas; in  order to determine the extent to which plant and animal varietiesare to 
'  be excluded from  patentability~ it should be spe~ified  th~t the exclusion concerns those 
varieties as· such and  that,  qcinsequent(y, .  it does  not prejudice the patentability  ~f 
-plants or ·animals  obtained  by  means  of a  process at  least one -stage  of which is 
essentia).ly microbiological,' irrespecti~e of the basic biological material to which that ' 
(18) 
- (19) 
(20); 
(21). 
process is :applied;·  ·'  - ·  ·  · 
- Whereas,  for ·the  purposes  of determining  whether. or not it-is  possible to  pa,tent -
essentially 'biological processes for obtaining plants or animals, hurrian  intervention.·_ 
and the etlects of that intervention on the resultobtaine.d must be taken into  a~.:wunl; 
Whereas national'patent laws for inventions. contain provisions M  to the criteria for 
.  allowing or excluding patentability, including provisions to the eff~  that a patent rm\y . 
.  _·not  be granted in respect of inventio~s whose publication' or exploitation would be 
•  contrary to public .policy or··moraHty;  ·  ·  ·  · 
Whereas  such a reference to 'public policy  and  moridity  should be included in  the 
operative part of  this Directive in order to bring ~ut  tli~ facUhat seine appli'tations of 
· biotechriologic~ inventions, by  Virtue_ of some of their .consequences or effects,  are 
capable of'pffending against them;  · 
Whereas it mu~t  be determined. whether .applications offend against  public policy and 
morality  in  each  specific  case·;  by  means of  an  appraisal  of the values  involved, 
whereby· the benefit to be derived from the invention, on the one hand, is weighed and. 
evaluated  against  any' risks  associated  therewith,  and  any  objections  based  on 
fundame~tal principles of  law,·. ori  ~e  other hand;· 
4 
·;-
'  '. (22)  Whereas the operative part of this Directive should also include an illustrative list of 
inventions excluded  from·  patentability  so  as to provide national-courts and  patent 
offices with a general guide to interpreting the reference to public policy o_r morality; 
{23)  Whereas such  moral  considerations must be given  great~r weight in appraising. the 
patentability of biotechnological inventions, both on account ;Of the subject-matter_ of 
this branch of science,  namely living  matter~ and because of the often far-reaching 
implications of tlte inventions to be examined; whereas these considerations do not, 
however, change the nature of  patent law as a primarily technical body of law and are 
no substitute for the other legal checks which biotechnological inventions are required 
to undergo from the start of their development or at the marketing stage, particularly 
with regard to safety; 
(24)  Whereas, in view of  the importance and the controversi~ nature of  the unprecedented 
(25) 
(26) 
(27) 
(28) 
(29) 
.. questi·ons raised by germ line gene therapy, it  ·is important to exclude unequivocally  .  . 
·from patentability any methods of treatment of human beings based on it;-
Whereas prqcesses for mo<iifying the genetic identity of  animals which are likely to 
cause them suffering or physical handicaps without any substantial benefit-to man or 
animal,  and  also  animals  resulting  from  such  processes  must  be  excluded  from 
patentability insofar as the suffering or physical handicaps inflicted on the animals 
concem.ed are out of proportion to the objective pursued;  - · 
Whereas, ·in view of  the fact that the function of a patent is to reward the inventor for -
his  creative  efforts by  granting ari  exclusive but time-bound  right,  and .  thereby  to 
encourage inventive activities, the holder of the patent should be entitled to prohibit 
the use of patented self-reproducible--material in situations analogous to those where 
, it would be permitted to prohibit such use of  patented, non-self-reproducible products, 
namely in  respect of the production of the patented product itself;- · 
Whereas it is necessary to provide for a first derogation from the rights of the -holder 
of the patent wf1en  the propagating material incorporating the protected invention is 
· sold to a farmer for farming purposes by the holder of the patent or with his consent; 
· whereas .that  initial  derogation  must authorize the farmer to use the product of his 
harvest for further multiplication or propagation on his own farm;  whereas the extent 
and the conditions of that derogation must be limited in accordance with the extent 
-and conditions set out in Regulation (EC) No 2100/94<s>; 
Whereas only the fee envisaged under Community plant variety rights as a condition· 
for applying the derogation from Community plant variety rights can be required of 
the farmer; 
Whereas,  however,  the holder of the patent may  def~nd his  rights against a farmer 
abusing the derogation  or against the breeder who has  developed the plant variety 
_incorporating the proteCted invention if the hitter fails to adhere to his commitments; 
OJ No L 227,  1.9.1994, p.  I. 
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. (31) 
(32) 
Whereas a second derogation from the rights of  the holder of the patent must authorize 
the farmer to use the protected livestock for breeding· purposes on his own farm,  in 
order to replenish their numbers; 
Whereas the extent and the conditions of that secbnd derogation should be determined  .  . 
by  national laws,  regulations and'. practices,  sinc.e  there is no Community legislation . 
on animal variety rights; 
.. Whereas, in the field of  exploitation of  new plant characteristics resulting from genetic· 
engineering,  guaranteed  access  must,  on  payment  of  a  fee,  be  granted  in  a 
Member State in the fonn of a compulsory licence where, in relation to the genus or 
species  concerned,  public  interest demands  the  exploitation· of the  plant  variety 
for which  the  licence  is  req4ested  and  the  plant  variety  represents  significant 
technical progress; 
(33)  Whereas,' in the field of the use of new plant characteristics resulting from new plant 
varieties in genetic engineering, guaranteed access against a fee must be granted in the 
fonn- of  a compulsory _licence  where .public interest demands the exploitation of the 
invention  for  which  the  licence  ts  requested  and  where  the  invention  represents 
significant technical progress,  · 
HAVE ADOPTED TillS DIRECTIVE: 
CHAPTER I 
Patentability· 
Article r 
1.  Member States  shall  protect biotechnological  inventions under national  patent law. 
Member States shall if necessary adjust their national  patent law to take account of 
"  the provisions of this Directive: 
2.  This  Directive  shall  be  without  prejudi<;e  to  national  and  Colilmunity  laws on  the 
. monitoring of research and of the use or commercialization of its results. 
Article 2 
For the purposes of this Directive: 
I. 
..  2 . 
"biological material  II means any material COntaining genetic iriforinatiofl and  C~pable 
of self-reproduction or of being reproduced in a biological system; 
"11,1icrobiological process" means any process involving·or perfonned upon or resulting 
in  microbiological  material;  a  process consisting of a  succession of steps  shall  be 
treated as  ~ microbiological  process if at least one essential  step  of the process  is 
microbiological;  ·  · ' 
6 3.  "essentially biol()gical  process for the  production  of plants or animals"  means ·any 
process which, taken as a whole, exists in nature or is .not more than a natural ,plant-
·breeding or animal-breeding process. 
Article 3 
1.  The human· body  and  its  elements  in their  natural  state  shall  not  -be  considered 
-patentable inventions. 
2.  Notwithstanding  paragraph  1,  the  subject  of an  invention  capable  of -industrial 
application which relates to an ·element isolated from the human ·body or ·otherWise 
produced by means of  ;a technical process shall be .patentable, even if  the structure of 
that element is identical to that of a natural element. 
Article 4 
I,  \fhe  sut>ject  of an jnvenfion  shall  :not  be considered  unpatentable .merely  on  th~ 
,grounds that it is composed ,of,  uses or is applied to biological material. 
2.  Bicilogical material, including ::plants and animals,  as well as -elements of plants  ~nd 
· animals obtained  ~y means of a process not ·essentially biological, except plant and 
animal varieties as such,  shall- be patentable. 
Article 5 
Microbiological  ·processes  and  products  obtained  •by  means  of .such  processes  shall 
:be ;patentable. 
Article 6 
Essentially biological'processes forthe ,production of,plants-or animals-shall not be  patent~bl~. 
ArtiCle '7 
.. 
Uses -of plant or. anirtuil varieties and processes for their production,  other than ·essen~ially 
biological processes for the _production -of plants.or animals, shall be .patentable.  · 
Article 8 
. The :subject ·of  a:n  invention· concerning  a :biological  materi_al  :Shall  not  be  considered  a ... 
discovery  or :tacking  in novelty  merely  on  the :grounds that ·it  already Jormed .part  of the 
natural world. 
Article ·9 
l. ·  Inventions shaH ;be considered unpatentable where -~xploitation would be -contrary to 
1ptiblic policy or morality; ·however; ·eJq>loitation shall not be deemed to l:>e so -contrary 
.merely ;&ecause ;it js prohibited .by law or regulation  .. 
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2.  ··On the basis of paragraph 1,  the following shall be. considered unpatentable: 
(a)  methods of human  tre~tment involv~ng germ line gene therapy; 
(b) 
c  • 
.  . 
processes for  modifying the genetic identity 'of at'imals which  are likely  to 
cause them suffering or physical handicaps without any  substantial benefit to  · 
man or animal, and also animals resulting from  sue~ processes, whenever the 
suffering  or  physical  handicaps· inflicted  on  the  animals  concerned  are 
disproportionate to the objective pursued. 
CHAPTER II 
Scope of proteetien 
Article 10 
1.  The  pr~tection conferred by  a' patent  o~-a. biological  material  possessing  specific 
characteristics as  a  result of the invention  shallextend to. any  biological  material 
derived  from  that biological  material  through  multiplication  or propagation  in  an 
. identical or divergent form and possessing those same characteristics.'  -
2.  The  -protection conferred by a patent -on  a process that enables a biological  material 
to be produced  possessing specific characteristics as  a  result of the invention  shall 
extend to biological material  directly obtained through that  proc~ss and to any  other 
biological  material  derived  from  the  biological  material  directly  obtained  through· 
multiplication or propagation· in  an  identical or divergent form  and possessing those 
same characteristics. That proteetion shall not  affect the exclusion from patentability . 
of plant and animal varieties as such, pursuant to Article 4(2). 
Article  11 
The protection. conferred  by  ·a  patent  on  a  product  containing  or  consisting  of genetic 
information shQll  extend to all  material~ save as provided for in Article 3(  1  )~ in which the 
- product is incorporated and in which the genetic information is contained and expressed. 
Article 12 
The  protection  referred  to in  Articles  10  and  i 1 shall  not extend to  biological  material-' 
obtained from the multipltcatioo or prop88ation ofbio&Cfiicat material marlc.eted in the territory 
of  .a Member State by  dte holder of the  patent or with  his consent, if the multiplicati()l'l or .. 
...  propagation fleOeiSarily  resutti from  the·. application for whf.ch  the biological  materiat  was 
~ed.  pnMoed chat me obtaieed material is not subtequentty used for other muttipl1catioo 
or~. 
.  ~  ' Article 13 
1. ·  By  way of derogation from Articles 10 and 11, the sale of propagating material to a 
farmer by the holder of the patent or with his consent for  agricultural  use implies 
authorization  for the farmer to .use  the product of his  harvest for reproduction  or 
propagation by him  on his own farm, the scope of and procedure for this derogation 
c~rresponding to those under Article 14 of Regulation (EC)No 2100/94. 
2.  By way of derogation from Articles ··10 and 11, the sale of breeding stock to a  farmer · 
by the holder of the patent or with his consent implies authorization for the farmer to 
use  the  protected  livestock  for  breeding  purposes  on  his  own  farm,  i~  order  to 
replenish their numbers. 
3.  The extent and the conditions of the derogation provided for in paragraph 2 shall be 
determined by national laws, regulations and  p~actices. 
CHAPTER ill 
Compulsory cross-licensing 
Article 14 
1.  Where a breeder cannot acquire or exploit a plant variety right without infringing a 
prior  patent, ·he may  apply  for  a  compulsory  licence for  non-exclusive  use of the 
invention  protected  by  such  patent  inasmuch  as  the  licence  is  necessary  for  the 
exploitation of the plant variety to be protected, subject to payment of an appropriate 
royalty. Member States shall provide that where such a licence is granted, the holder 
of the  patent  will  be  entitled  to  a  cross-licence  on  reasonable  terms  to use  the 
protected variety. 
2.  Where the holder of a patent on a biotechnological invention cannot exploit it without 
infringing a prior plant variety right, he may apply for a compulsory licence for non:. 
exclusive use of the plant variety protected by that right,  subject to payment of an 
appropriate royalty. Member States shall proviqe that where such a licence is granted, 
the holder of the variety right will. be entitled to· a cross-licence on reasonable· terms 
to use the protected invention. 
3.  Applicants for the licences referred to in paragraphs 1 and 2 must demonstrate that: 
(a)·  they have applied unsuccessfully to the holder of the patent or of the plant 
variety right to obtain a contractual licence; 
(b)  exploitation  of the  plant variety  or the  invention  for  which  the licence  is 
requested  is  dictated  by  the  public  interest  and  the  plant  variety .  or  the 
invention constitutes significant technical progress. 
9 4·.  Each Member State shall designate the authorityor authorities responsible for granting 
the licence.  The licence shall  be granted  principally  for  Lhc  supply  of the domestic 
market of the Member State which has granted the licence. 
CHAPTER IV 
Deposit, access and re-deposit of a  bi()logical material 
Article 15 
1.  Where an invention involves th·e use of or concerns a biological material which is not 
available to the public and which) cannot be described in a patent application· in such 
a  mann~r as to enable the invention to be reproduced by a person skilled in the art, 
.  the description shall be considered inadequate for  the~ purposes of patent law unless: 
(b) 
(c) 
the biological  material  has been  deposited,  no later than the date on which 
the  patent  application  was  filed,  with  a  recognized. depositary  institutioh. 
At  least· the  international  gepositary  authorities  whic~  · acquired  this  status 
by  virtue  or Article 7  of the  Budapest  Treaty· of 28  April. 1977  on  the 
· International Recognition of  the Deposit of Micro-organisms for the Purposes 
of Patent Procedure,  hereinafter  referred to ;:ts  the "Budapest Treaty",  shall 
be recognized; 
the application as filed contains such relevant information as·is available to the 
·  applican~ on the chanicteristi~s of the biological material deposited; 
the  patent  application  states~ the name of the depositary  institution  and  the 
accession number. 
2.  Access to the deposited biological material shall be provided through the supply of 
a sample:  · 
(a) 
(b) 
(c) 
up to the first publication of  the patent application, only to those persons who 
are authorized under national patent law; 
between  the  first  publication  of the  application  and  the  gnmting  of the 
patent, to anyone  requesting  it or,  if the applicant  so .  requests,  only  to an· 
independent expert; 
after  the  patent  has  been  granted,  and  notwithstanding  revocation  ~or 
cancellation 'of the patent, to anyone requesting it. 
10 3.  The sample shall be supplied only if the person requesting it undertakes, for the term 
during which the patent is in force: 
(a)  not to make it or any matter derived from it available to third parties; and 
(b)  not.touse it or any biological matter derived from it except fot experimental 
purposes 
unless  the  -patent  holder  or  applicant,  as  applicable,  e~pressly  waives  such  an 
undertaking. 
4.  At the applicant's request, where an application is refused or  withdrawn, access to the· 
deposited material shall be limited to an independent expert for twenty years from the 
date on which the patent:application was filed.  In that case, paragraph 3 shall apply. · 
5.  The applicant's requests referred to in point (b) of  paragraph 2 and in paragraph 4 may 
only be made up to .the date on which the technical  pr~arations for publishing the· 
patent application are -deemed to ·have been completed. 
Article 16 
I.  If the biological  material  deposited  in  accordance  with  Article 14  ceases to be 
available from  the recognized depositary  institutions, a new  deposit of the materia] 
shall ·be :permitted on the same .tetins as those laid down :in "the  Budapest Treaty. 
2.  Any  new  d~posit ·shall  be  accompanied  by  a  statement si_gned  by  the  applicant 
certifying  that  ·the  newly  deposited  biolqgical  material  is  the  same .as  that 
originally .deposited. 
·CHAPTER\' 
'Burden of  :proof 
ArtiCle  1"7 
1.  If  the -sl:lbject-matter of a .patent is a _process for 'Obtainiqg a new ·,product, then, when 
the same :product ,is ,produced :.by any other ;patty, 1t .shal'l, jn ,the absence ·of:proof to 
,the .contrary, ;be deemed to have :been obtained ~~y the ipatented ,process. 
2.  ln· .the .adduction .of  .;pro0f rt:o ;the con  tracy., ,the !legitim~  ~nterests  :of  ,tQ.e 'defendant :m . 
.proteeti~g ;his :manufacturi:qg ·:and business :secrets. ·shall !be -:taken :into ;account. I. 
CHAPTER VI 
Final provisions 
Article  18 
Member  States  shall  bring  into  force  the  laws,  regulations ·and  administrative 
provisions n~cessary to comply with this Directive not later than 1 Jahu!f.ry :2000.-They 
shallimmediately inform the Commission thereof 
When Member States adopt these. provisions, these shall  contain a reference to this 
Directive  or  shall be accompanied  by  such  reference  at the time  of their. official 
publication. The. procedure for  such reference shall be adopted by Member States. 
2.  Member States shalt communicate to the Commission the text of the main provisions 
of national law which they adopt in the field covered by  this Directive. 
Article .19 
This Directive shalt·cnlcr into force on the twentieth day  following that of  its  publication in 
the Otlicial Journal  of the European Communities.·  ·  · 
Article 20 
This Directive is addressed to the Member States. 
Done at Brussels, 
For the European Parliament 
The President 
For the Council 
The President • 
• 
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IMPACT OF THE-PROPOSAL 
ON BUSINESSES  . 
·(and particularly SMEs)_ 
L  WHY IS  CO~UNITY  LEGISLATION NECESSARY? 
In order to harmonize, at Community level, Member States' legislation on the legal 
protection of biotechnological inventions, with· a view to  achieving  the  following 
objectives:  . (  · 
(a) . to  improve  the  operation of the internal  market for  patented biotechnological 
:products,. so: as to  ensure their .free movement;  .  . 
(b)  to prevent distortions of competition for firrns .using biotechnology; 
.·(c)  to ensure that research and development in biotechnology enjoy appropriate legal . 
protection thanks to  harmonization of Member States' legislation; 
(d)  to  i~provethe competitiveness of industry using biotechnology; 
(e)  to  tak~·due account of the ethical dimension ofi>iotechnological inventions.  · 
.  '  . .  ~~  '  . 
2.  WHICH INDUSTRIES WILL BE  AFFECTED? 
.  ' 
(a)· The  measure  will  benefit  manufacturers  of liiotechnological  products,  and 
· particularly firms that base their ·activities on research.  -
(b) . Accor<;ling to a study published by ·.Ernst & Young in 1995, 485  firrp.s  would be · 
affected in. Europe.  Of those,  81% employ  less than  50 ·people,  and45% were 
founded after 1986. They cover-a wide range of activities: pharmacy, chemicals, 
agriculture,  foodstuffs,  the  environment  and. plant.  While  investment  in  the 
research and development of new biotecJmological products is high, the  return 
on  that  investment  is  uncertain  because  the  legal protection  offered  by  the 
. '  system  of patents  for  invention  is  not  as  clear-cut  as  in  other  areas  of 
technology. The proposed measure is such that it would apply to all firms using 
biotechnology, whaJever their size.  · 
(c)  There is no  reason_" to  suppose  that  particular  geographic~! areas  will b-enefit 
. more than others from. the  measure.  · 
3  •.. WHAT  l\fUST  BUSINESSES  DO  IN  ORDER  TO  COMPLY  WITII  lHE 
MEASURE? 
Th'e  firins affected will not be required to  take any  special steps in order to  benefit · 
. from the planned legislative harmonization .. 
4.  WHAT ARE THE LIKELY ECONOMIC EFFECfS OF TilE MEASUR,E? 
(A) .  ON  EMPLOYMENT 
Clarifying  the  legislative  environment  for  biotechnological  inventions  will 
provide innovative firms in the various industries using biotechnology with an 
incentive to continue or even increase their Investment in research. Establishing 
an  appropriate  legal ·  fra~ework  for  the  protection  of  biotechnologic?J 
inventions  will  encourage  innovation.  Consequently, . the  boost  given  to 
employment will be. most noticeable in. the research field. ·  -
36 (B) .. ON  INVESTMENT AND  THE ESTABLISHMENT OF NEW BUSINESSES 
Harmonization of  legal protection for biotechnologic3.I inventions should enable 
the firms  concerned to feel far more  .. certain about recouping  their costs and 
investment.  Once  it  is  clear  that  patent  law  also  applies  in  full  to 
. biotechnological products, patent holders will  realize that the possible return 
on  sums  invested  in  perfecting  such  products  enjoys  a  much  greater  legal 
guarantee. Patent law does  not, of course, guarantee that there will be a market 
for  any  given  product,  but  at  least  research  findings  cannot  be  turned  to 
advantage by  those  not involved in  making the  necessary  initial  investment. 
This is a powerful incentive for setting up new businesses in order to undertake 
leading-edge research in biotechnology and then market the results. The sector's 
great promise is borne out by Ernst & Young's figures, which show that many 
of the firms concerned are newly established and small. 
-
(c)  ON  1HE COMPETffiVENESS OF BUSINESSES 
The  Commission  White Paper Growth,  competitiveness,  employment - The 
challenges and ways fmwara into  the  21st century<
1> places special  emphasis 
on  the  responsibility  of governments  and  the  Community  in  creating  an 
environment that is  as  conducive as  possible to  businesses'  competitiveness. 
Firms  using  biotechnology  must  be  able  to  contribute  increasingly  to  the 
European Union's balance of payments surplus. In order to do so, they need to 
be able  to  occupy  a position that accurately· reflects both their domestic and 
international competitiveness, so  as  not to  be  left behind by  developments in 
other parts of the world. 
5.  DOES  THE  PROPOSAL CONTAIN  MEASURES  THAT TAKE PARTICULAR 
ACCOUNT OF SMEs? 
. The harmonization measures· contained in  the proposal are not particularly designed 
to  assist small and medium-sized enterprises, although they  will  be. able to  benefit 
. equally from them. 
6.  .  CONSULTATION 
(I) 
(. 
In drawing up the proposal, the Commission departments consulted widely with the 
sectors concerned and· with various interest groups. In line with the wishes expressed 
by  Parliament, the  purpose of  the  consultations was to  ensure that the  legislation 
governing  patents· for  invention  would  be  clear  and  unambiguous,  that  it  would 
contain precise definitions, and that it would distinguish clearly between unpatentable 
discoveries and patentable inventions. 
The Commission departments were in  contact with, or received written submissions 
from:  the  European  Patent Office (EPO),  the. Union of Industrial  and Employers' 
Confederations  of Europe  (UNICE),  the  European  Board  of Chemical  Industry 
Federations  (EBCIF),  the  European  Federation  of  Pharmaceutical·  Industry 
Associations (EFPIA), the European Secretariat of National Bioindustry Associations 
(ESNBA), the Seed Committee of the Common Market (COSEMCO), Greenpeace, 
the  Chartered  Institute  of Patent  Agents,  the  Animal  Cell  Technology  Platform 
(ACTEP), the Green Industry Biotechnology Platform (GIBiP), the Senior Advisory 
Group on Biotechnology (SAGB), the Agence Nationale pour la Valorisation de la 
Recherche (ANV  AR),  Friends of the Earth  (Europe),  the Bioindustry  Association 
(BIA) and the British Union for the Abolition of Vivisection (BUAV). 
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